Introduction
Adeno-associated virus type 2 (AAV-2) is a human parvorvirus with a 4.7 kb single-stranded genome which is being widely tested for an application in gene therapy. Vectors derived from AAV-2 are exploited as an alternative delivery system for the introduction of recombinant genes into mammalian cells. 1 Wild-type AAV-2 can integrate in a site-specific manner into human chromosome 19, 2 a desirable feature for the treatment of enzyme deficiencies and chronic virus infections. After excision of the coding region rAAV has a packaging capacity of 50-119% of the wild-type genome 3, 4 with an optimal length of 4.1-4.9 kb, 5 which makes it an ideal viral vector for the delivery of small genes such as antisense and ribozyme genes. Reports of successful transduction have been published for a variety of primary cells such as airway epitheliums, [6] [7] [8] brain, 9 muscle tissue, 10 and also for hematopoietic cells. 11 Biological properties of recombinant AAV-2 derived vectors (rAAV) are not as well studied as those of more established viral vectors such as, for example, retroviral or adenoviral vectors. 12 Recombinant AAV vectors can transduce quiescent cells, 13 which applies to neuronal cells 14 as well as certain immature cells of the hematopoietic system. 15 The CD34 + hematopoietic cell population contains the progenitors for CD4 + Correspondence: G Sczakiel Received 31 December 1998; accepted 28 March 1999 cells and thus contains the target cells for a gene therapy against AIDS. In particular for rAAV, more information is required on its tissue tropism, transduction efficiency, and the strength and time-course of gene expression after transduction of primary cells. Recent studies on the tissue tropism of rAAV indicate a large cell type-specific variability of transduction efficiency. 16 In summary, rAAV represents a vector system for which more characteristics regarding its application for human cells including hematological cell subsets and its biological properties should be collected.
In order to provide a tool to study transduction of primary target cells for an anti-HIV gene therapy and to enable one to look at the efficacy of HIV-directed antisense/ribozyme sequences, we designed fusions with reporter genes that were inserted into rAAV constructs. Endogenous transcription of the fusion genes led to expression of luciferase or gfp, respectively, and transcripts contained functional antisense or ribozyme sequences in cis indicating that these constructs are appropriate to study transduction efficiency, time-course and levels of gene expression as well as anti-HIV-1 efficacy in relevant cells including human CD4
+ cell populations and their precursors.
Results
In order to follow transduction by rAAV, the expression of HIV-1-directed vector-encoded genes and possible antiviral effects on the single cell level, we aimed endogenously to co-express in cis an indicator function and an HIV-1-directed inhibitory function. Even at low transduction efficiency, this strategy should enable successful identification of rAAV-transduced cells with expression of the fusion gene and monitoring of expression of the introduced gene at the single cell level and on a quantitative basis.
Fusions between indicator genes and HIV-1-directed antisense or ribozyme sequences To monitor endogenous expression of HIV-1-directed antisense RNA and hammerhead ribozymes in mammalian cells, we fused the coding sequences of the indicator gene gfp or luciferase with the effective HIV-1-directed antisense sequence AR6 17, 18 or hammerhead ribozyme 2as-Rz12. 19 The fusion genes are under the transcriptional control of the constitutive HCMV immediate-early promoter/enhancer element and are terminated by SV40 splice and polyadenylation signals which are derived from the expression cassette of the plasmid pKEX-2-XL. 20 The resulting constructs were inserted in both orientations between the inverted terminal repeats (ITRs) of the AAV-2 clone psub201 21 as schematically depicted in Figure 1 .
The fusion genes between gfp/luciferase and antisense/ribozymes are functionally active Transient transfection with a set of luciferase-coding constructs ( Figure 2a ) into 293T cells showed that the expression levels of the luciferase-containing fusion genes were equal to or up to four-fold greater than measured with the parental construct pKEX-luci (Figure 2a ). Furthermore, a significant influence of the orientation of the expression cassette within the pAAV constructs as well as the type of fused antisense or ribozyme sequence was observed. Highest expression of luciferase was observed when the fusion sequence contained the HIV- 1-directed antisense portion AR6 and the fusion gene was oriented towards the 5Ј ITR (Figure 2a ). To test whether the orientation dependence of indicator gene expression was related to vector-derived sequences or the plasmid vector backbone, rAAV vector sequences containing fusion genes in either orientation were excised by cleavage of plasmid DNA with PvuII. The recognition sequence for PvuII is located at positions outside the ITR elements. Fragments were purified by agarose gel electrophoreses and transfected into 293T cells. The resulting indicator gene expression reveals the orientation dependence observed and thus suggests that possible cis elements affecting indicator gene expression are positioned within the rAAV vector portion. Since the sequences of the fusion transcripts are not dependent on the orientation of the expression cassette, we favor the hypothesis that remaining ITR sequences contain DNA cis elements that influence neighboring gene expression in an orientation-dependent manner or that both ITR elements are not completely identical.
Expression of gfp was measured by transient transfection of the constructs shown in Figure 2b into 293T cells and subsequent analysis of fluorescence intensity of gfpexpressing cells by FACS. It became obvious that fusion of gfp with the antisense sequence AR6 did not significantly affect fluorescence intensity whereas fusion with the ribozyme sequence Rz12 reduced fluorescence intensity by a factor of approximately five with respect to the parental gfp-coding plasmid pEGFP-C1 (Figure 2b) .
The ability of the fusion genes to inhibit replication of HIV-1 was tested after transient transfection and microinjection of test DNA together with infectious proviral HIV-1 DNA into human cells. First, we tested effects of the luciferase-coding fusion genes lacking the ITR elements in cis by microinjection into human SW480 cells (Figure 3a) . The concentrations of DNA were chosen such that inhibition was in a range that was suitable to detect differences quantitatively, ie inhibition levels were inter- mediate but not complete. The extent of inhibition was retained for the ribozyme-containing fusion gene. For the luciferase/antisense fusion pluci-AR6, an approximately three-fold loss of inhibition was measured (Figure 3a) .
From the ITR-containing constructs only those with the (−)-orientation were tested for HIV-1 inhibition as most of them showed a higher level of marker gene expression than their (+)-counterparts ( Figure 2 ). All luciferase fusion genes within the rAAV constructs (pAAV-luci . . ., Figure 1 ) which contain the ITR sequences in cis exhibited a substantial loss of inhibition ( Figure 3b ) whereas all gfp fusions within the rAAV context showed the same extent of inhibition that was measured for the parental antisense/ribozyme constructs. These data suggested further study of the gfp-antisense/ribozyme fusion genes.
Generation of infectious recombinant AAV
To produce infectious rAAV particles, a system was used that provides all necessary helper functions for rAAV particle formation by plasmid-coded genes 22 thereby avoiding the use of infectious adenovirus. The concentrations of infectious particles (IP) after one CsCl gradient purification followed by dialysis was typically equal to or greater than 5 × 10 8 IP/ml. The recovery from the cell lysate and supernatant of infectious rAAV from 10 8 293T packaging cells was 10 8 -10 9 IP which corresponds to 1-10 IP per packaging cell. Between 10% and 50% of the total recovery of rAAV could be isolated from the supernatant of the packaging cell cultures.
Expression of gfp in transduced cells resulted in a distinct population of fluorescent cells that could be detected by FACS analysis (Figure 4a ) although the intensity of fluorescence varied within one order of magnitude. The gfp-AR6 fusion gene resulted in the strongest fluorescence of all gfp fusion constructs which is consistent with the influence of antisense/ribozyme sequences measured after transient transfection (Figure 2b ). If one assumes that transcription levels are similar for all contructs one could conclude that either mRNA stability or the modified C-terminal sequence of GFP encoded by the antisense sequence of AR6 (AHNRL instead of the original sequence GTAGPGSTGSR encoded by the plasmid pEGFP-C1) could be responsible.
The GFP fluorescence of transduced cells clearly distinguished them from the untransduced ones ( Figure 4a ) and at lower MOIs there was a linear correlation between the percentage of transduced cells and the quantity of virus used (Figure 4b ). This enabled us to use FACS analysis for the determination of the concentration of infectious particles prepared from the gfp fusion constructs (see Materials and methods). The fluorescence intensity increased only slightly up to a MOI of about 0.3 and much faster at higher MOIs (Figure 4b ). This pattern would be expected if we assume that at lower MOIs the number of transduced cells increases and at higher MOIs a higher number of rAAV genomes enter a cell thereby causing higher gfp expression.
Absence of acute and long-term negative selective pressure on rAAV-transduced human cells The potential benefit of HIV-1-directed therapeutic genes could be extinguished by acute or long-term suppression of cell growth caused by transduction with rAAV, the endogenous expression of transduced genes, or by unknown kinds of negative selective events within a mixed population of transduced and untransduced cells. To test whether this is relevant for the rAAV constructs GFP were measured by FACS. The percentage of GFPpositive cells after transduction at a MOI of 2 decreased within 3 to 5 days from 70% to almost constant levels of approximately 0.2%. This frequency remains similar at a lower initial MOI (Figure 5b ). The decrease of the percentage of initially gfp-expressing cells within the first 4 to 6 days after transduction cannot be explained by shortterm toxicity by rAAV and seems to indicate the frequency of stable transduction. The ratio of stably gfpexpressing cells as well as the expression levels of gfp remained constant for more than 7 weeks (Figure 5b ) suggesting that there is no negative selection for stably rAAV-transduced cells with stable expression of the gfp fusion genes in the presence of untransduced cells.
It is noteworthy that the detection of rAAV-transduced and gfp-expressing cells is surprisingly sensitive. A number of control experiments with comparable gfp-and lacZharboring harboring rAAV constructs indicates that the sensitivity of gfp expression after transduction of HeLa or 293T cells is approximately 10-to 100-fold higher when compared with detectable expression of lacZ (data not shown). This increased sensitivity is also due to the fact that gfp-specific fluorescence in transduced cells is at least one order of magnitude above background levels of FACS analysis and thus allows detection of gfp-positive cells even at low rates of transduction (Ͼ1%). The increased sensitivity of detection of rAAV-gfp-transduced cells helps to overcome some of the rAAV-specific limitations including those linked to the insufficient gene expression which is ascribed to insufficient second-strand sysnthesis of single-stranded vector DNA in transduced cells. 23 Hence, the apparent efficiency of transduction of, for example, HeLa cells by gfp-harboring rAAV particles is substantially greater than that in the use of lacZ-harboring particles.
Suppression of HIV-1 replication in rAAV-transduced cells
The ability of the gfp/antisense-harboring rAAV particles to inhibit HIV-1 replication after transduction of HIV-1-permissive cells was tested in HeLaP4/CCR5 which are susceptible to HIV-1 infection with macrophage-tropic strains. Cells were first transduced at varying MOI of rAAV and challenged with HIV-1 at a MOI of 0.2 1 day later. At a MOI of 5 and 25 of rAAV we observed a reproducible reduction of HIV-1 production of approximately two-to three-fold ( Figure 6 ). The extent of inhibition of HIV-1 was dependent on the dose of rAAV and at a MOI of rAAV equal to or smaller than 1, an approximately two-fold increase of HIV-1 production versus rAAV-free controls was observed ( Figure 6 ). This somewhat surprising AAV-specific increase of HIV-1 replication in coinfected cells under specific conditions is reminiscent of other reports and will be discussed later.
Preliminary attempts to transduce potential target cells for a gene therapy against AIDS by rAAV include primary human macrophages, T lymphocytes, and the CD34 + cell population containing more immature hematopoietic cells. For all three hematopoietic cell subsets transduction by rAAV-gfp-AR6− was tested at varying MOIs (Table 1) . For T lymphocytes, we observed a strong inter-individual variability which is consistent with earlier studies. 24 Transduction of primary macrophages was negative at the conditions used here whereas primary CD34 + cells (Teichmann et al, unpublished) isolated from some but not all donors were accessible for rAAV and thus, suitable for the rAAV vector system. In some cases and at high MOIs of rAAV, over 10% of the CD34 + cell subset could be transduced and expressed gfp as measured by FACS (Teichmann et al, unpublished).
Discussion
In this work, fusion genes between the indicator-coding sequences of luciferase or gfp and the HIV-1-directed antisense sequence AR6 or the ribozyme Rz12 were inserted into rAAV vectors and were shown to be packageable to form infectious particles. The packaging efficiency was at a level 10 8 IP/ml which is in the range of that described by others. 22 Cells transduced by rAAV can be identified by FACS which enables one to follow transduction and gene expression in a quantitative manner with a resolution on single cell level and over a long time-period. In the packaging cell culture GFP protein is expressed from the rAAV DNA and thus could be contained within the preparation of infectious particles. Therefore, it is critical to exclude that apparent transfection as measured by FACS is due to GFP protein contained within the rAAV sample. 25 There is, however, evidence excluding this possibility: a mock particle preparation with a gfp construct lacking the ITRs contains GFP protein at similar levels as the preparations of infectious rAAV as can be observed in the microscope. Neither with CsCl gradientpurified rAAV nor when using a crude cell lysate without further purification could a transfer of GFP protein be observed by FACS analysis of mock-transduced HeLa cells (data not shown). As similar conditions were used for the transduction of T lymphocytes and macrophages we exclude the possibility of fluorescence that is not due to transduction. If one considers rAAV as a vehicle to introduce HIV-1-directed recombinant genes into target cells for a gene therapy against AIDS, one should be aware of reports on the negative or positive interference between wtAAV-1 and its gene products with the replication and gene expression of HIV-1. [26] [27] [28] [29] For example, the somewhat puzzling observation of increased HIV-1 replication after low-dose transduction by rAAV (here at a MOI of 1, Figure 6 ) is consistent with a report describing that wtAAV has a potentiating effect on HIV-1 replication in the absence of helper functions provided by co-infected adenovirus but not in its presence. 27 Both findings suggest that the AAV-mediated increase of HIV-1 replication is related to a cellular environment which does not allow replication of AAV. In this study we used rAAV constructs which lack the complete protein-coding sequences of wtAAV. Therefore, the positive interference between rAAV and HIV-1 might be linked to the ITR elements or to residual AAV-specific proteins originating from the packaging cells, which we cannot completely rule out. However, there are a number of other reports describing successful inhibition of HIV-1 by rAAV vectors harboring genes for a ribozyme 30 or anti-gp 120 antibodies. 31 This supports the view that the rAAV vector system is worth testing as a potentially suitable vector for cell populations relevant for gene therapy against AIDS. However, when regarding relevant primary cell subsets, more insights are necessary into the high donor-dependent variability and often unsatisfactory low transduction efficiency before the rAAV vector system can be successfully developed and used to deliver recombinant therapeutic genes including HIV-1-directed constructs into human CD34 + cells and progenies thereof.
This work describes recombinant AAV vectors that can be produced at high titers and express indicators and HIV-1-directed inhibitory RNA in cis. These constructs can be used to follow transduction by rAAV and subsequent gene expression enabling the study of anti-HIV-1 efficacy in subsets of hematological cells and even at low transduction efficiency. The observation that rAAVtransduced cells do not show any selective disadvantage in mixed cultures of transduced and untransduced cells suggests the use of rAAV constructs described here for more detailed studies on their tropism and efficacy, in particular in the use of primary human CD34
+ and CD34 + cell populations.
Materials and methods
Cells, viruses and DNA MT4 cells 32 were maintained in RPMI (Sigma, Mü nchen, Germany). HeLa, 33 SW480, 34 HeLaP4/CCR5 35 and 293T 36 cells were cultured in Dulbecco's modified Eagle's medium (Sigma). All media were supplemented with 10% heat-inactivated fetal bovine serum (GIBCO, Karlsruhe, Germany) as well as penicillin and streptomycin (100 U/ml and 100 g/ml, Sigma). Infectious HIV-1 strain NL4-3 was produced by transfecting HeLaP4/CCR5 with the proviral DNA pNL4-3. After 4 days, the supernatant was used to infect MT4 cells. After a further 3 days incubation, the medium was collected and the concentration of infectious HIV-1 was titrated on HeLaP4/CCR5 by X-gal staining.
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For HIV-1 infection cells seeded 1 day before were incubated with the virus in a small volume of medium for about 4 h. After washing twice with PBS fresh medium was added.
Fusion genes gfp/luci + as/rz The plasmid pRz12 harbors the HIV-1 gag-directed hammerhead ribozyme 2as-Rz12 19 and was obtained by inserting the blunted HindIII/SacI fragment from plasmid pBS29-Rz12 19 into the SmaI site of pKEX-2-XL 20 which is located between the HCMV immediate-early enhancer/promotor element and the SV40 polyA signal.
The luciferase expression plasmid pKEX-luci is also based on pKEX-2-XL and contains the luciferase-coding sequence from pMAMneo-LUC (Clontech, Heidelberg, Germany) inserted into the SmaI site.
To generate the fusion constructs between indicator gene sequences and HIV-1-directed antisense or ribozyme sequences, the NheI/KpnI fragment from the pEGFP-C1 vector (Clontech) or the NcoI/KpnI fragment from pKEX-luci were filled in and inserted into the vectors pAR6 18 or pRz12 that had been linearized with KpnI or XbaI, respectively. The orientations of the inserts were assessed by restriction analysis. The resulting four plasmids pluci-AR6, pluci-Rz12, pgfp-AR6 and pgfp-Rz12 ( Figure 1 ) were used to excise the fusion genes (SpeI/Eco47III for the luciferase constructs or SpeI/BamHI, partial digestion, for gfp constructs). Fragments were blunted and inserted into the filled in XbaI site between the ITRs of plasmid psub201 21 giving rise to plasmids pAAV-gfp-AR6+/−, pAAV-gfp-Rz12+/−, pAAV-luci-AR6+/−, pAAV-luci-Rz12+/− (Figure 1 ). To produce control particles containing the gfp gene without antisense sequences, the plasmid pAAV-gfp-AR6− was digested with AccI and religated to obtain pAAV-gpf. The sequence of the 5Ј ITR of pAAV-gfp-AR6− was confirmed by sequencing to be as published. 39 Indicator gene expression Expression of gfp was qualitatively assessed by fluorescence microscopy (DM IL microscope; Leica, Wetzlar, Germany) directly on the tissue culture plate. For quantification, cells were trypsinized, resuspended in precooled FACS medium (PBS, 3% FCS, 0.1% sodium azide) and analyzed by fluorescence activated cell sorting (FACSort). The cutoff of FACS analysis was set such that less than 0.1% of GFP-negative cells were within the scoring window. To measure expression of luciferase, semiconfluent HeLa cells were transduced in a 24-well plate with rAAV. 
HIV-1 replication in human cells
To test for HIV-1 inhibition of the fusion genes, plasmids were either comicroinjected as described recently 18 or cotransfected together with infectious proviral DNA pNL4-3. 37 Briefly, for comicroinjection SW480 cells were grown on glass coverslips and 50 cells were comicroinjected with the proviral DNA at 30 ng/l and the test plasmids at a five-fold molar excess. The coverslips were transferred to a 48-well plate. After 1 day 10 5 MT4 cells were added per well resulting in a final volume of 1 ml. After a further 4 days incubation virus production was measured by a commercial p24 ELISA (Organon, Boxtel, Belgium). As a control, a plasmid with a CMV-driven luciferase gene without any antisense sequences was comicroinjected with the proviral DNA. To compare data, we expressed the p24 production as the percentage of the control which is set to be 100%.
For transfection experiments 293T cells were seeded at a density of 5 × 10 4 per well in a 48-well plate. After 1 day cells were contransfected with 150 ng pNL4-3 per well and the five-fold molar excess of the test plasmid by calcium phophate as described. 40 To measure HIV-1 replication after infection, target cells were seeded at low density in a 48-well plate and incubated with HIV-1 1 day later at a MOI of 0.02. After 3 h the virus suspension was discarded, the cells were washed twice with 1 ml of PBS and 1 ml of fresh medium was added. Samples were taken immediately as controls for the p24 ELISA that was performed on days 3 and 4 after infection.
Adenovirus-free production of rAAV Infectious rAAV particles were generated 22 and purified as described recently. 41 293T cells were seeded on 15 cm dishes and cotransfected with 18 g of the vector construct and 18 g of the helper plasmid pTGMA [438] . Six hours later, the medium was replaced by fresh medium. Three days after transfection the medium was collected and the cells harvested by scraping. After three freezethaw cycles in a dry ice/ethanol bath and 37°C water bath the cells were sonified at 50% duty cycle on level 3 (Sonifier 250, Branson, Danbury, CT, USA) until no clumps were visible. The cell debris was removed by low speed centrifugation, CsCl was added to the supernatant to a final density of 1.38 g/ml, and the solution was underlayed with a cushion of 1.5 ml CsCl in PBS (1.5 g/ml). After centrifugation in a SW41Ti rotor (Beckman, Palo Alto, CA, USA) at 252 000 g for 22 h fractions of 700 l were collected and their refractive index determined. The six fractions with the index closest to 1.3715 (corresponding to a density of 1.40 g/cm 3 ) were dialyzed (Spectra/Por Membrane MWCO:6-8000, Roth, Karlsruhe, Germany) twice against PBS and once against DMEM medium for at least 3 h each at 4°C and stored at −20°C.
The rAAV-gfp titers were determined by transducing 10 5 HeLa cells in 0.5 ml per well in a 24-well plate with varying amounts of virus suspension. After 1.5 days the cells were trypsinized, resuspended in 0.5 ml cold FACS medium, counted and analyzed by FACS as described above. From a number of 10 000 cells the percentage of green fluorescent cells was determined and samples with a percentage up to 25% positive were scored. We calculated the titer by multiplying the percentage of positive cells by the total number of cells and the input volume.
Cell proliferation
Proliferation of cells was monitored by BrdU incorporation which was measured with a commercial ELISA (Boehringer Mannheim). Briefly, cells were incubated in a 96-well plate with 10 m BrdU for 2 h. After fixation and DNA denaturation for 30 min at room temperature cells were labeled with anti-BrdU-peroxidase for 1 h. After thorough washing the substrate solution was added and the reaction was stopped 15 min later by addition of 1 m H 2 SO 4 . The absorption was measured at 450 nm.
Isolation and transduction of primary cells
Macrophages and T lymphocytes were isolated as described previously. 41 Briefly, peripheral blood mononuclear cells were obtained by centrifugation of blood samples on a Ficoll gradient. Macrophages were separated by plastic adherence and T lymphocytes by E-rosetting. For this purpose the non-adherent cell fraction was incubated with sheep erythrocytes, the resulting complexes were centrifuged over a Ficoll gradient and finally the T lymphocytes were depleted from the erythrocytes by acid lysis. CD34 + cells were obtained from enriched blood samples by immunomagnetic separation with a CD34 + Progenitor Cell Isolation Kit (MACS; Milteny Biotec, Bergisch Gladbach, Germany). All primary cells were transduced directly after enrichment and were kept in RPMI medium (Sigma). Macrophages were not cultured in the presence of cytokines, cultures of T lymphocytes were supplemented with IL-2 (20 U/ml, Promocell, Heidelberg, Germany) and cultures of CD34
+ cells with IL-3 (20 ng/ml, Promocell, IL-6 (40 ng/ml, Promocell) and SCF (50 ng/ml, Promocell).
